Tuesday, November 13, 2012
Galectin Therapeutics Inc., of Norcross, Ga., presented preclinical data on the mechanism of action of GR-MD-02, its lead galectin inhibitor in non-alcoholic steatohepatitis (NASH), or fatty liver disease. Galectin-3 protein expression was markedly increased in animals with NASH, and those levels were reduced to barely detectable levels following treatment with GR-MD-02.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.